Clinical trial
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)
NCT00153582 · Charite University, Berlin, Germany, Other · Unknown status
Key facts
| NCT number | NCT00153582 |
|---|---|
| Title | WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) |
| Official title | Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Myelodysplastic Syndrome |
| Intervention type | Biological |
| Interventions | WT1 126-134 peptide |
| Enrollment | 25 |
| Start date | Apr 1, 2002 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 22, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: